PYCARD and cholangiocarcinoma: As loss of ASC due to promotor-methylation impairs prognosis in cholangiocarcinoma [15] or lung cancer [16], we aimed to assess whether ASC is differently expressed in metastatic versus non-metastatic primary cutaneous SCC.